ALSO READGranules India inches up after USFDA nod for Ibuprofen tablets Granules India gains after its plant receives inspection report from USFDA Granules India gains after entering into product in-licensing pact with US firm Granules Hyderabad plant successfully closes USFDA inspection Insecticides (India) gains after entering into product marketing agreement
Meanwhile, the S&P BSE Sensex was down 124.25 points or 0.45% at 27,549.61
On BSE, so far 3.79 lakh shares were traded in the counter as against average daily volume of 1.36 lakh shares in the past one quarter. The stock hit a high of Rs 125.60 and a low of Rs 121.10 so far during the day. The stock had hit a record high of Rs 164.45 on 1 December 2015. The stock had hit a 52-week low of Rs 101.25 on 12 February 2016. The stock had outperformed the market over the past 30 days till 14 October 2016, rising 2.26% compared with Sensex's 2.6% fall. The scrip, however, underperformed the market in past one quarter, sliding 17.89% as against Sensex's 0.59% decline.
The small-cap company has equity capital of Rs 21.72 crore. Face value per share is Rs 1.
Granules India said that the company's Gagillapur facility, Hyderabad, has successfully completed U S Food and Drug Administration (USFDA) inspection without any observations. This facility manufactures finished dosages (FDs) and pharmaceutical formulation intermediates (PFIs).
On a consolidated basis, Granules India's net profit rose 36.51% to Rs 38.96 crore on 6.56% growth in net sales to Rs 343.50 crore in Q1 June 2016 over Q1 June 2015.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)